logo
How one woman took on ‘Big Pharma' and (mostly) won

How one woman took on ‘Big Pharma' and (mostly) won

Yahoo2 days ago

As a sales rep for drug manufacturers Questcor, Lisa Pratta always suspected the company's business practices weren't just immoral but illegal, too, as she explains in 'False Claims — One Insider's Impossible Battle Against Big Pharma Corruption' (William Morrow).
But this was the final straw.
At a patient event in Freehold, NJ, in August 2011, a young woman walking with a cane asked Pratta if the drug she sold, Acthar, could help with her multiple sclerosis. When the woman mentioned she was a mother to two babies and also had been diagnosed with lymphoma, Pratta broke down.
'I couldn't say anything,' Pratta tells The Post. 'I just went to the ladies' room and cried.
'And that was the turning point. I knew my days of keeping my mouth shut were over.'
Pratta began working for Questcor in 2010 as the sales rep in the Northeast region for Acthar, a drug which helped relieve autoimmune and inflammatory disorders. 'If prescribed correctly, Acthar could help people walk again. And talk again,' writes Pratta.
But, she adds, 'Questcor made more money when it was prescribed incorrectly.'
They would do anything to sell Acthar.
From paying doctors to prescribe it to using bogus research studies proclaiming its miraculous efficacy, they were so successful that Achtar's price rose from $40 per vial in 2000 to nearly $39,000 in 2019 — an increase of 97,000%.
Pratta's determination to do the right thing was partly the result of a traumatic childhood tainted by physical and sexual abuse.
'I had to fight for myself and develop that inner strength,' she says. 'I needed tenacity.'
That tenacity was put to the test when Pratta began to uncover the extent of Questcor's corruption.
Some sales reps were making up to $4 million a year and, in turn, kept the physicians doing their bidding in a life of luxury. 'The greed had just taken over. They took them on scuba diving trips and bought clothes and shoes for their wives. One guy bought his doctor a brand new Armani suit and expensed it to Questcor,' she recalls.
'And I'm going to TJ Maxx to buy my shoes.'
Though she had deliberated about exposing Questcor, Pratta worried about the ramifications. 'That's all I could think about,' she says. 'I was a single parent, mother of a special needs son and had a ton of debt from my divorce.
'The last thing I needed was to be fired and homeless.'
The impetus to act came from former colleague, Pete Keller, who, also concerned about Questcor's methods, had decided to tell the authorities.
Now he needed Pratta, who was still working there, to act as a 'relator' and feed information to lawyers, including health care fraud attorneys Marc Orlow and Ross Begelman.
To make the case, Pratta compiled as much evidence as possible, surreptitiously making notes at sales meetings and patient programs.
'I used to write notes on the palm of my hand under the table,' she explains. 'If I was at a cocktail party and somebody confessed what they were doing was bribery, I would write it on a napkin in the bathroom or even on my pants.
'I ruined a lot of suits.'
Given the financial might of the industry she was battling, Pratta became acutely aware of her own safety.
Before she turned whistleblower, Pratta researched other relators to see what happened to them. 'Just to see if anybody was murdered,' she explains. 'You know, a mysterious accident or a car blowing up.'
Consequently, she become hyper-vigilant.
'I would see cars sitting at the end of my block and I just got paranoid,' she says. 'I was watching even more when I went in stores or the parking lot. I got a dashcam, too.'
In January 2012, the Department of Justice began a preliminary investigation into Questcor. Soon, federal agents began calling at Pratta's colleagues' homes and she had to feign shock. But, she writes, 'If I was the only one in the company who didn't get an early-morning visit from the Feds, that wasn't exactly helping me keep my cover.'
Soon, Pratta's clandestine role became second nature to her. 'It didn't feel like I was still working for the government. It was like being married to my ex — they were never around, and there was no communication,' she writes.
After Questcor was acquired by Irish pharma-giant Mallinckrodt in 2014, pressure to deliver even higher sales increased exponentially and with it came even greater disregard for ethics.
In 2017, after she was repeatedly bullied by her boss, Pratta went to HR to complain but was fired soon after, although they maintained it was a corporate restructure, just to avoid a wrongful termination case.
'Ironically, I wasn't fired because I was a double agent feeding information to the Department of Justice. Instead, they got rid of me for the offense of daring to speak out about an abusive manager,' she writes.
In March 2019, the Department of Justice served a 100-page lawsuit against Mallinckrodt, alleging illegal marketing of Acthar, bribing doctors to boost sales and defrauding government health care programs
It also mentioned Pratta's role in the case, meaning her long-held anonymity was now public knowledge.
'I didn't mind that my former bosses knew; I just wished I could have seen their faces when they put it all together. I hoped they felt that their lives were suddenly out of their control.
'The way the Acthar patients felt.'
In the wake of the lawsuit, Mallinckrodt filed for bankruptcy, a move which immediately halted all legal action against them, much to Pratta's frustration.
Worse still, a member of the New Jersey plumbers' union with MS had his union file a class action lawsuit against Mallinckrodt — and, as Pratta's identity was now revealed, and she was a New Jersey resident, he named her in it.
While four of the five defendants were companies, Pratta was the only individual named.
'The plumbers' union was not messing around,' she writes. 'They were pissed, and rightly so. In 2018, they'd paid $26,100.28 for one dose of Acthar for one of its members.'
While that lawsuit against Pratta was ultimately thrown out, 'by the time it was finally dismissed, I was left with almost $42,000 in attorneys' fees,' she says.
Nor did Pratta receive anywhere near the amount of compensation she could have been entitled to as a whistleblower.
When Mallinckrodt settled out of court in March 2022, agreeing to pay just $26.3 million for violating the False Claims Act — far less than the amount had the case reached trial — it meant Pratta's percentage share was even smaller.
Worse still, it would now be paid in installments, once a year for the next eight years. 'In reality, if I averaged it all out, it was as if I'd just stayed employed for another ten years instead of losing my job,' she reflects.
For Pratta, though, the long, expensive journey to justice had been worth all the anxiety and sleepless nights.
In fact, she has no regrets whatsoever about doing what she did.
'Now I sleep like a baby,' she laughs.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cuomo flip-flops on flip-flop, supports NYC congestion pricing a year after opposing it
Cuomo flip-flops on flip-flop, supports NYC congestion pricing a year after opposing it

New York Post

time2 hours ago

  • New York Post

Cuomo flip-flops on flip-flop, supports NYC congestion pricing a year after opposing it

Mayoral hopeful Andrew Cuomo brazenly flip-flopped on congestion pricing yet again, saying he now supports the Manhattan toll program he initially fought for – after last year calling for it to be paused. Cuomo insisted in a New York Times interview Tuesday that he not only can't think of any issues he changed his mind on, but his opinion on congestion pricing has never wavered. The former governor had approved the controversial plan to toll vehicles entering Manhattan south of 60th Street, but last year wrote an op-ed for The New York Post urging leaders to pump the brakes on the first-in-the-nation program. Advertisement Andrew Cuomo claimed that his opinion on congestion pricing has never wavered — despite brazenly flip-flopping on the issue. Robert Miller But when asked by The New York Times whether he supports congestion pricing now that it shows signs of success, Cuomo gave a blunt response: 'Yes.' Earlier in the interview, Cuomo echoed the arguments he made in The Post op-ed. He contended his past opposition was rooted in concern that congestion pricing would drive people into unsafe subways. Advertisement 'All I said was, let's study this before we do it in this moment, to make sure people aren't going to say, 'you know what, another reason for me to stay home,'' he said. The apparent flip-flop quickly rankled at least one Democratic operative. 'Andrew Cuomo has no core principles, he'll say whatever it takes to claw his way back into power,' the operative told The Post. 'He's exactly why so many people have lost faith in politics: a flip-flopping wannabe king who ran to the Hamptons when things got tough.'

Crypto airdrops: How to find and claim the next free token drops
Crypto airdrops: How to find and claim the next free token drops

New York Post

time2 hours ago

  • New York Post

Crypto airdrops: How to find and claim the next free token drops

Cryptocurrency airdrops have emerged as a popular way for blockchain startups to promote new crypto tokens and attract users to their projects. The guide below has all the details that crypto enthusiasts should know about airdrops, how they work and how to avoid scams. Airdrops are best understood as a way for crypto startups to raise awareness while launching new virtual currencies. The startups will send tokens to the virtual 'wallets' of users who sign up. The coins are usually distributed for free or in exchange for a service, such as posting on social media about the crypto project. Advertisement It's a long shot, but if the crypto coin surges in popularity and gains a following online, its value can skyrocket, providing a windfall for the user. 'The upside of legit airdrops can be huge, some early users of protocols like Arbitrum, Uniswap, or Celestia made thousands of dollars for actions they took months before token launch,' Cryptex cofounder and CEO Joe Sticco told The Post. While potentially lucrative, airdrops can be very high-risk and are sometimes associated with 'rug pulls' or 'pump and dump' schemes, while project leaders quickly sell off their holdings after launch. Advertisement Experts stress that crypto users should be cautious and conduct due diligence to ensure that they are being offered by a reputable outlet. 'Risks include phishing, spam tokens or even smart contract exploits, so tread carefully,' Cryptex's Sticco said. 'If it sounds too good to be true, it probably is.' Users should look carefully at the URLs of project websites to ensure they look legitimate and attempt to identify token launches that come with 'transparent roadmaps and real use cases,' according to Patrick Young, an executive at airdrop distribution tool Galxe. Are You Crypto Curious? How to start crypto trading today Best Wallet Download a trusted exchange app — Start by choosing a licensed crypto exchange. We recommend starting with the Best Wallet app, available for both iOS and Android. Create and verify your account — Sign up using your email, Google, or Apple ID. To complete registration, you'll need to verify your identity with a government-issued ID and enable two-factor authentication (2FA) for added security. Fund your account — Deposit money into your account by linking a bank account or credit card or even using gift cards. Choose an option that best fits your lifestyle. Buy your first cryptocurrency — Use the app's marketplace or swap tool to purchase crypto by entering the ticker symbol — like BTC for Bitcoin or ETH for Ethereum — and follow the prompts to complete the transaction. Choose how to store your crypto — Decide whether you'll keep your crypto in the exchange, move it to a digital wallet (hot wallet), or store it offline (cold wallet) for extra protection. LEARN MORE Advertisement It's also critical for users to protect their crypto wallets by only connecting to verified pages. Users should never share their private wallet keys or seed phrases — the sequence of words used to access their crypto wallet. 'If anyone — especially someone claiming to be from the project — asks for your seed phrase, that's a major red flag,' Young said. Some experts suggest using an alternative wallet as a safeguard against potential fraud. 'The best advice is to look for projects evincing transparency, admin accountability, and engagement from project devs/managers,' added Peter C. Earle, senior economist at the American Institute for Economic Research. Advertisement For those interested in hunting for crypto airdrops, experts advise looking out for insider communities on social media platforms, including X, Discord and Telegram, or on specialized crypto sites that are set up to provide access for airdrops. Alec Strasmore, the founder of Epic Loot Labs, suggests that users study the 'tokenomics' of specific projects to get a sense of key details, such as how much supply of a given token is being given away in an airdrop. Community excitement and levels of engagement of public posts serve as a way to gauge whether certain projects may take off. 'General sentiment about the project also matters a lot because it determines how many people want to buy the token once its live,' Strasmore said. Blockchain startups will usually announce an airdrop online and detail any requirements to participate, such as having users follow a certain social media account or sign up to their website. Users provide their wallet address and receive a specific amount of coins, which varies from project to project. From there, they can buy, sell or hold the coins as they see fit. Look for wallets that are compatible with a wide array of blockchains and cryptocurrencies, have strong security settings and are non-custodial – meaning the user, not the platform, has control of their own private keys. Top options include Best Wallet, which distributed its own token $BEST via airdrop, as well as popular services like MetaMask, Exodus and Rabby. Leading exchanges like Kraken, Coinbase, and Binance occasionally support airdrops. Other sites like CoinMarketCap, Galxe and also curate airdrops. New York Post Approved Our pick — 60+ Chains. Total Control. Best Wallet The Best Wallet app puts security first with biometric logins, two-factor authentication, and full non-custodial control — so you hold your keys, not just your coins. With support for thousands of altcoins across 60+ blockchains, it pairs top-tier security with powerful, user-friendly tools — making it the safest, most innovative way to HODL, swap, and manage your crypto. Learn More 108M+ Users Worldwide Coinbase Coinbase is building a more inclusive financial future for over a billion people, enabling them to trade, stake, spend, and transfer crypto on a secure and trusted platform. It powers the on-chain economy with essential infrastructure, global access, and a commitment to fair, responsible innovation. Learn More 114.9% BTC Reserve Ratio Kraken Kraken takes crypto security seriously, with FIDO2-compliant Passkey logins, encrypted communications, and customizable API permissions that keep your account firmly in your control. With no phone-based recovery, time-locked global settings, and real-time threat monitoring, it's built to protect your assets at every layer. Learn More $232B Platform Assets Robinhood Robinhood Crypto offers a user-friendly platform for trading and transferring digital assets, including the ability to securely and easily send and receive crypto to and from external wallets. With its self-custody Robinhood Wallet, it manages crypto holdings across multiple blockchains, including Ethereum, Bitcoin, and Solana. Learn More 20% of Global Crypto Secured Ledger Ledger is a leading provider of secure hardware wallets, offering devices like the Ledger Nano X and Ledger Stax that protect private keys offline using industry-leading Secure Element chips and a proprietary operating system. Paired with the Ledger Live app, manage over 5,500 digital assets, including cryptocurrencies and NFTs. Learn More 100M+ Users & Growing lets you buy, sell and trade over 400 cryptocurrencies, including Bitcoin and Ethereum, with zero-fee USD deposits, wire, and Apple/Google Pay. With a user base exceeding 140 million, the platform gives advanced trading options, a self-custodial wallet through Onchain, and industry-leading security certifications. Learn More $53T+ in Transactions Uphold Uphold is a multi-asset trading platform that enables users to buy, sell, and swap over 360 cryptocurrencies, 27 fiat currencies, and four precious metals, all in a single step. With features like assisted self-custody via the Uphold Vault, staking rewards up to 16.8%, and real-time reserve transparency, it offers a secure and versatile experience for both beginners and seasoned investors. Learn More The New York Post may receive revenue from affiliate/advertising partnerships for sharing this content and/or if you click or make a purchase.

Significant NIH Grant Will Help Lamassu Biotech Advance Life-Saving Pancreatitis Treatment For Dogs
Significant NIH Grant Will Help Lamassu Biotech Advance Life-Saving Pancreatitis Treatment For Dogs

Yahoo

time4 hours ago

  • Yahoo

Significant NIH Grant Will Help Lamassu Biotech Advance Life-Saving Pancreatitis Treatment For Dogs

New 'One Health' Grant Could Help Man's Best Friend with Groundbreaking Research for Presently Untreatable Condition, Provide Key Data for Human Treatment CLEVELAND, June 3, 2025 /PRNewswire/ -- Momentum continues to build for Lamassu Biotech's pioneering treatment protocol for acute pancreatitis in canines. The private, clinical stage biopharmaceutical company has received a $2.7 million "One Health" grant from the National Institutes of Health (NIH) to support its efforts to advance the development of RABI-767, a novel therapeutic that could provide hope for dog owners whose beloved companions are suffering from the condition, as well as potential human treatment. Acute pancreatitis in humans leads to over 330,000 hospitalizations annually in the United States and also affects nearly 1.8 million dogs, causing severe illness and high mortality rates. Currently, there are no FDA-approved treatments for acute pancreatitis in either animals or humans. Lamassu's new veterinary division, Lamassu Pets, in collaboration with The Ohio State University College of Veterinary Medicine, has commenced clinical trials focused on spontaneous canine acute pancreatitis (CAP). The trials will evaluate how RABI-767 can directly target the pancreas to reduce complications, improve recovery, and potentially save thousands of animal lives. RABI-767, originally developed at the Mayo Clinic, has demonstrated significant preclinical efficacy, reducing mortality and improving recovery outcomes for humans. "This deadly disease has vexed researchers and physicians for decades, but this investment by the NIH could bring new hope for effective treatment for both humans and dogs. The NIH resources reflect the government's appreciation for the growing size and importance of the veterinary market. It also recognizes the value of One Health, dual track trials that can benefit both animals and human patients," said Gabi Hanna, MD, CEO and co-founder of Lamassu Biotech and Lamassu Pets. "The research Ohio State will be conducting through its canine patients will not only help man's best friend but will expand our understanding of the disease and inform human treatment strategies as well." Findings from the canine trials will directly inform dosing, safety, and efficacy strategies for an ongoing Phase 2 human trial, creating a rare synergy between veterinary science and human healthcare. Additional details on the canine clinical trial's progression will be forthcoming. About Lamassu BiotechLamassu Biotech is a pioneering pharmaceutical company focused on developing innovative treatments for severe and unmet medical needs. With decades of experience, Lamassu specializes in advancing transformational treatments from concept to bedside with efficiency and precision. At Lamassu, we believe in the transformative power of science and the hope it brings to patients and families. Learn more at CONTACT:Krysia Lenzo917-428-8923396136@ View original content to download multimedia: SOURCE Lamassu Biotech Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store